rgx-104
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02922764)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- LXR-betaAGONIST
NR1H2 agonist
- Liver X receptorAGONIST
Liver X receptor agonist
May be selective for LXR beta
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1- Mol. weight
- 596.09 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL573677 ↗
Also known as
- rgx-104
- rgx-104
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05911308 | Phase 1 | Nov 30, 2023 | AstraZeneca, Inspirna, Inc., University of North Carolina at Chapel Hill |
| NCT02922764 | Phase 1 | Nov 1, 2016 | Inspirna, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inspirna, Inc. | For profit | 2 | 1 | 1 | 2016 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2023 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1